BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

Contributed by: Business Wire

Logo

Tags

Research

FDA

Clinical Trials

Biotechnology

General Health

Pharmaceutical

Health

Science

Oncology

Other Science

ASCO 2026, Solid Tumor Pipeline

More Like This

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025